Efficacy of auranofin as an inhibitor of desmoid progression

Anticancer drugs and molecular targeted therapies are used for refractory desmoid-type fibromatosis (DF), but occasionally cause severe side effects. The purpose of this study was to identify an effective drug with fewer side effects against DF by drug repositioning, and evaluate its efficacy. FDA-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Kan, Nishida, Yoshihiro, Hamada, Shunsuke, Shimizu, Koki, Sakai, Tomohisa, Ohkawara, Bisei, Alman, Benjamin A., Enomoto, Atsushi, Ikuta, Kunihiro, Koike, Hiroshi, Zhang, Jiarui, Ohno, Kinji, Imagama, Shiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279441/
https://www.ncbi.nlm.nih.gov/pubmed/35831372
http://dx.doi.org/10.1038/s41598-022-15756-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279441/
https://www.ncbi.nlm.nih.gov/pubmed/35831372
http://dx.doi.org/10.1038/s41598-022-15756-9

Ejemplares similares